

# **Tromboembolismo venoso ‘incidental’ en el paciente oncológico**

**C. Font**

Servicio de Oncología Médica  
Hospital Clínic

Mayo 2011

# Trombosis venosa ‘incidental’

- Diagnóstico radiológico sin previa sospecha clínica.
- Emerge en los 90's con el desarrollo del TAC
- 2-5 % de los TAC's
- ++ TEP > Ilíacas Cava Troncos braquiocefálicos
- ++ pacientes con cáncer
- **‘Trombosis incidental’ --> Radiólogos**
- **Estudios clínicos de trombosis --> ‘Trombosis sintomática’**

# Unsuspected pulmonary embolism on CT scanning: yet another headache for clinicians?

Sujal R Desai

*Thorax* 2007;62:470-472

Arguments for and against treatment of small unsuspected pulmonary emboli

- Presunción de que són 'pequeños' los TEP incidentales ?  
Pulmón como filtro de pequeños TEP 'fisiológicos'?
- Són necesarias más exploraciones complementarias?  
ECOdoppler venoso? AngioTAC?
- Tratamiento anticoagulante?  
Decisión clínica dar 'significado clínico' a los hallazgos radiológicos  
Pragmáticos: tratar  
  
Riesgo retrombosis / sangrado

# CHEST®

Official publication of the American College of Chest Physicians



## Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

Clive Kearon, Susan R. Kahn, Giancarlo Agnelli, Samuel Goldhaber,  
Gary E. Raskob and Anthony J. Comerota

*Chest* 2008;133:454-545  
DOI 10.1378/chest.08-0658

The online version of this article, along with updated information and services can be found online on the World Wide Web at:  
[http://chestjournal.org/cgi/content/abstract/133/6\\_suppl/454S](http://chestjournal.org/cgi/content/abstract/133/6_suppl/454S)

2.6.1. In patients who are unexpectedly found to have asymptomatic DVT, we recommend the same initial and long-term anticoagulation as for comparable patients with symptomatic DVT (Grade 1C).

5.1.6. In patients who are unexpectedly found to have asymptomatic PE, we recommend the same initial and long-term anticoagulation as for comparable patients with symptomatic PE (Grade 1C).

## Unsuspected Pulmonary Emboli in Cancer Patients: Clinical Correlates and Relevance

*Casey L. O'Connell, William D. Boswell, Vinay Duddalwar, Amy Caton, Lisa S. Mark, Cheryl Vigen, and Howard A. Liebman*

A B S T R A C T

### Purpose

Advances in computed tomography (CT) scanning have led to the detection of unsuspected pulmonary emboli (PE) on routine cancer staging scans. We hypothesized that these patients had signs or symptoms suggestive of PE that may have been overlooked by their health care providers.

### Patients and Methods

A retrospective chart review was performed on 59 patients found on routine cancer staging CT scans to have unsuspected PE. Information on patient demographics, malignancy characteristics, risk factors for venous thromboembolism (VTE), and symptoms was recorded. A retrospective case-control analysis was then performed using two age- and stage-matched control patients for each patient who had similar staging CT scans performed during the same period.

From the Division of Hematology,  
Department of Medicine; Department  
of Radiology; and the Department of  
Preventive Medicine, University of  
Southern California-Keck School of  
Medicine, Los Angeles, CA.

Submitted March 13, 2006; accepted  
August 15, 2006.

Supported by a grant from the Vanoff  
Family Foundation and Max Gondon.

Authors' disclosures of potential con-  
flicts of interest and author contribu-  
tions are found at the end of this  
article.

Address reprint requests to Howard A.

- Incidental = Asintomática?
- Estudio retrospectivo    n= 59 TEP incidentales + cáncer  
n= 92 pacientes oncológicos control sin TEP
- 44% TEP incidental tenían síntomas atribuibles a TEP  
75% si añadian 'fatiga'

**Table 3.** Signs and Symptoms Among Patients With and Without Unsuspected PE

Symptom	Case Patients		Control Patients		Odds Ratio*	<i>P</i> *
	No.	%	No.	%		
Chest pain	3	7	6	7	0.94	.93
Fatigue	25	54	18	20	4.88	.0002
Limb pain or swelling	7	15	14	15	1.02	.97
Shortness of breath	10	22	7	8	5.03	.02
Tachycardia or palpitations	7	15	12	13	1.21	.72

Abbreviation: PE, pulmonary emboli.

\*Calculated using conditional logistic regression matching by age and stage, and using additional adjustment for age within each matched set.

## **Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients**

C. Font<sup>1\*</sup>, B. Farrús<sup>2,3,4</sup>, L. Vidal<sup>1</sup>, T. M. Caralt<sup>5</sup>, L. Visa<sup>1</sup>, B. Mellado<sup>1,3</sup>, D. Tàssies<sup>3,6</sup>,  
J. Monteagudo<sup>6</sup>, J. C. Reverter<sup>3,4,6</sup> & P. Gascon<sup>1,3,4</sup>

Estudio prospectivo observacional Mayo 2006-Abril 2009

Servicio de Oncología Médica: Hospitalización / H de día / Urgencias

Tumor sólido + evento tromboembólico de nuevo diagnóstico

Tratamiento anticoagulante sintomáticos / incidentales

# Resultados I

N=340 pacientes (193 hombres y 147 mujeres)

N=227 (67%)  
Sospecha clínica

N=113 (33%)  
TAC programado

N=19 (17%) sintomáticos

N=246 (72%) SVT

N=94 (28%) IVT



	SVT (%) N = 246 (72)	IVT (%) N = 94 (28)	P
Mean age ± SD (years)	60.8 ± 11.7	63.7 ± 10.5	0.035
Male	135 (55)	58 (62)	NS
Smoking	131 (53)	46 (49)	NS
Diabetes	24 (10)	13 (14)	NS
Hypertension	70 (28)	27 (29)	NS
Dyslipidemia	37 (15)	14 (15)	NS
Previous VT before cancer	14 (6)	4 (4)	NS
Inpatients	37 (15)	10 (11)	NS
Performance status			NS
ECOG 0	42 (17)	10 (11)	
ECOG 1	91 (37)	41 (44)	
ECOG 2	71 (29)	33 (35)	
ECOG 3	42 (17)	10 (11)	
Tumor type			NS
Lung	59 (24)	26 (28)	
Colorectal	41 (17)	11 (12)	
Breast	39 (16)	10 (11)	
Genitourinary	29 (12)	14 (15)	
Gynecological	23 (9)	11 (12)	
Upper gastrointestinal <sup>a</sup>	21 (8)	11 (12)	
Head and neck	17 (7)	3 (3)	
Other <sup>b</sup>	17 (7)	8 (8)	
Tumor stage			0.01
Clinical remission	38 (15)	6 (6)	
Locoregional	47 (19)	11 (12)	
Metastatic	161 (65)	77 (82)	
Therapies			
Chemotherapy	165 (67)	50 (53)	0.018
Radiotherapy	62 (25)	27 (28)	NS
Hormonotherapy	20 (8)	11 (12)	NS
Major surgery	33 (13)	13 (14)	NS
ESA	58 (24)	24 (25)	NS

# Localization of the VT index event

SVT (%)

N=246

IVT (%)

N=94

## Localization

Femoropopliteal

116 (47%)

6 (6%)

Pulmonary embolism

63 (26%)

56 (60%)

Subclavian and / or jugular

45 (18%)

5 (5%)

Proximal arms

10 (4%)

1 (1%)

Superior cava vein

7 (3%)

1 (1%)

Inferior cava vein

2 (1%)

16 (17%)

Iliac veins

0

9 (10%)

Catheter indwelling

43 (18%)

1 (1%)

# Radiological findings in patients with PE


	SVT (%) N=63	IVT (%) N= 56	P
Central arteries	33 (52%)	36 (64%)	NS
Bilateral	41 (65%)	23 (41%)	0.009
Multiple PE	55 (87%)	42 (75%)	0.08
Single peripheral PE	6 (10%)	7 (13%)	NS
CT signs of lung infarction	3 (5%)	2 (4%)	NS
Associated DVT in CT scans	8 (13%)	4 (7%)	NS

# Outcome variables

	SVT (%) N=246	IVT (%) N=94	p
<b>Anticoagulant therapy</b>			0.003
Indefinite LMWH	127 (52%)	48 (51%)	
Indefinite LMWH / OAC	55 (22%)	18 (19%)	
6 months LMWH	53 (21%)	13 (14%)	
≤ 3 months LMWH	11 (4%)	15 (16%)	
<b>Major bleeding</b>	24 (10%)	7 (7%)	NS
<b>Venous rethrombosis</b>	44 (18%)	10 (11%)	NS
<b>Dead</b>	175 (71%)	67 (71%)	NS
Cancer progression	133	58	
Infection	12	2	
Venous thromboembolism	13	3	
Arterial thrombosis	3	0	
Bleeding	14	4	
<b>Mean survival after The VT index event</b>	469 ± 445	497 ± 405	NS

# Hemorragias mayores


1B



■ Log Rank NS


# Supervivencia global

1C



■ Log Rank NS

# Retrombosis venosa



- Log-Rank  $p=0.043$

- Regresión de Cox:

Sintomática

$p=0.009$   
RR 2.366

Estadio del cáncer  $p=0.009$

Cáncer locorregional RR 1.275

Cáncer metastásico RR 2.55

# Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Marcello Di Nisio<sup>1</sup>; Noemi Ferrante<sup>1</sup>; Michele De Tursi<sup>2</sup>; Stefano Iacobelli<sup>2</sup>; Franco Cuccurullo<sup>1</sup>; Harry R. Büller<sup>3</sup>; Beatrice Feragalli<sup>4</sup>; Ettore Porreca<sup>1</sup>

<sup>1</sup>Department of Medicine and Aging; Centre for Aging Sciences (Ce.S.I.), "University G.D'Annunzio" Foundation, Chieti, Italy; <sup>2</sup>Department of Clinical Oncology, "University G.D' Annunzio" Foundation, Chieti, Italy; <sup>3</sup>Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands; <sup>4</sup>Dipartimento di Scienze Cliniche e Bioimmagini, Istituto di Scienze Radiologiche, Università degli Studi G. d'Annunzio, Ospedale SS. Annunziata, Chieti, Italy

Retrospectivo      Cohorte de pacientes que inició quimioterapia      N=1921

Type of malignancy	Patients	Incidental VTE	Symptomatic VTE	Overall VTE
Breast	764 (40)	5 (0.6)	7 (0.9)	12 (1.6)
Colorectal cancer	492 (26)	21 (4.3)	13 (2.6)	34 (6.9)
Lung	205 (11)	14 (6.8)	5 (2.4)	19 (9.3)
Genitourinary	95 (5)	5 (5.3)	2 (2.1)	7 (7.4)
Upper gastrointestinal	87 (4)	2 (2.3)	5 (5.7)	7 (8.0)
Pancreas, liver	68 (3)	3 (4.4)	3 (4.4)	6 (8.8)
Ovary	58 (3)	3 (5.2)	0 (0)	3 (5.2)
Prostate	56 (3)	2 (3.6)	2 (3.6)	4 (7.1)
Gynaecological	40 (2)	6 (15)	2 (5.0)	8 (20.0)
Others	56 (3)	1 (1.8)	0	1 (1.8)
Total	1921 (100)	62 (3.2)	39 (2.0)	101 (5.3)

# Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer

F. DENTALI,\* W. AGENO,\* M. G. PIERFRANCESCHI,† D. IMBERTI,† A. MALATO,‡ C. NITTI,§  
A. SALVI,§ S. SIRAGUSA,‡ A. SQUIZZATO,\* J. VITALE\* and G. AGNELLI¶

## Estudio retrospectivo multicéntrico

Table 1 Baseline characteristics of included patients



	Asympomatic VTE	Symptomatic VTE	No VTE
Number	60	120	60
Male sex, n (%)	31 (52)	65 (54)	29 (48)
Mean age (SD)	65.8 (10.9)	69.6 (11.5)	68.6 (10.2)
Advanced stage, n (%)	58 (96.6)	112 (93.3)	58 (96.6)
Cancer site	28 gastroenteric 8 pulmonary 6 lymphatic 6 breast 12 others	37 gastroenteric 17 pulmonary 15 lymphatic 16 breast 35 others	18 gastroenteric 14 pulmonary 5 lymphatic 12 breast 11 others
Venous thrombosis location	37 PE + DVT 9 isolated DVT 14 isolated PE	20 PE + DVT 96 isolated DVT 4 isolated PE	—
Antithrombotic treatment	44 therapeutic LMWH 4 prophylactic LMWH 12 LMWH + warfarin	94 therapeutic LMWH 0 prophylactic LMWH 26 LMWH + warfarin	
Cancer treatment	55 chemotherapy 2 hormonal therapy 15 radiotherapy 9 erythropoietin	101 chemotherapy 7 hormonal therapy 30 radiotherapy 13 erythropoietin	49 chemotherapy 6 hormonal therapy 12 radiotherapy 8 erythropoietin
Mortality, n (%)	27 (45)	57 (47.5)	16 (26.7)

## ORIGINAL ARTICLE

# Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning

C. O'CONNELL,\* P. RAZAVI,† M. GHALICHI,\* S. BOYLE,‡ S. VASAN,§ L. MARK,\* A. CATON,¶  
V. DUDDALWAR,\*\* W. BOSWELL,\*\*\* K. GRABOW†† and H. A. LIEBMAN\*

Retrospectivo N=70 TEP incidentales compara con 137 controles sin TEP




## Risk of Recurrent Venous Thromboembolism and Mortality in Patients With Cancer Incidentally Diagnosed With Pulmonary Embolism: A Comparison With Symptomatic Patients

Paul L. den Exter, José Hooijer, Olaf M. Dekkers, and Menno V. Huisman


Retrospectivo

N=144 TEP sintomático

N=51 TEP incidental




**Fig 1.** Cumulative risk of recurrent venous thromboembolism for patients with cancer with incidental versus symptomatic pulmonary embolism (PE;  $P = .77$ ).



**Fig 2.** Kaplan-Meier cumulative survival curve until overall death for patients with cancer with incidental versus symptomatic pulmonary embolism (PE;  $P = .70$ ).

# CONCLUSIONES

1. **Trombosis venosa incidental en el paciente oncológico:**  
Un tercio del total de eventos trombóticos  
La mitad de los TEP
  
2. **Incidentales = asintomáticos o paucisintomáticos**
  
3. **Tromboembolismo venoso incidental NO es pequeño**  
Afectación de arterias centrales  
Mayoría TEP múltiples → refuerza la decisión de tratar
  
3. **Datos de estudios retrospectivos y observacionales:**  
Pronóstico similar a trombosis sintomática?  
Menor retrombosis?
  
4. **Son necesarios estudios prospectivos para evaluar el tratamiento óptimo de estos pacientes.**



Gracias !